391 related articles for article (PubMed ID: 26582244)
1. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
Wang Y; Yang F; Shen Y; Zhang W; Wang J; Chang VT; Andersson BS; Qazilbash MH; Champlin RE; Berenson JR; Guan X; Wang ML
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26582244
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
McCarthy PL; Holstein SA; Petrucci MT; Richardson PG; Hulin C; Tosi P; Bringhen S; Musto P; Anderson KC; Caillot D; Gay F; Moreau P; Marit G; Jung SH; Yu Z; Winograd B; Knight RD; Palumbo A; Attal M
J Clin Oncol; 2017 Oct; 35(29):3279-3289. PubMed ID: 28742454
[TBL] [Abstract][Full Text] [Related]
4. Autologous transplantation and maintenance therapy in multiple myeloma.
Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomized controlled trials.
Gao M; Gao L; Yang G; Tao Y; Tompkins VS; Wu X; Xu H; Zhan F; Shi J
Int J Clin Exp Pathol; 2014; 7(6):3073-80. PubMed ID: 25031726
[TBL] [Abstract][Full Text] [Related]
6. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
Palumbo A; Hajek R; Delforge M; Kropff M; Petrucci MT; Catalano J; Gisslinger H; Wiktor-Jędrzejczak W; Zodelava M; Weisel K; Cascavilla N; Iosava G; Cavo M; Kloczko J; Bladé J; Beksac M; Spicka I; Plesner T; Radke J; Langer C; Ben Yehuda D; Corso A; Herbein L; Yu Z; Mei J; Jacques C; Dimopoulos MA;
N Engl J Med; 2012 May; 366(19):1759-69. PubMed ID: 22571200
[TBL] [Abstract][Full Text] [Related]
7. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Qiao SK; Guo XN; Ren JH; Ren HY
Chin Med J (Engl); 2015 May; 128(9):1215-22. PubMed ID: 25947406
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide versus thalidomide based regimens as first-line therapy for patients with multiple myeloma.
Zou Y; Sheng Z; Niu S; Wang H; Yu J; Xu J
Leuk Lymphoma; 2013 Oct; 54(10):2219-25. PubMed ID: 23394458
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
Raza S; Safyan RA; Lentzsch S
Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
12. Consolidation and Maintenance Therapies for Newly Diagnosed Multiple Myeloma in the Era of Novel Agents.
Nathwani N; Larsen JT; Kapoor P
Curr Hematol Malig Rep; 2016 Apr; 11(2):127-36. PubMed ID: 26893062
[TBL] [Abstract][Full Text] [Related]
13. Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies.
Chen M; Zhao Y; Xu C; Wang X; Zhang X; Mao B
Ann Hematol; 2018 Jun; 97(6):925-944. PubMed ID: 29500711
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Palumbo A; Bringhen S; Larocca A; Rossi D; Di Raimondo F; Magarotto V; Patriarca F; Levi A; Benevolo G; Vincelli ID; Grasso M; Franceschini L; Gottardi D; Zambello R; Montefusco V; Falcone AP; Omedé P; Marasca R; Morabito F; Mina R; Guglielmelli T; Nozzoli C; Passera R; Gaidano G; Offidani M; Ria R; Petrucci MT; Musto P; Boccadoro M; Cavo M
J Clin Oncol; 2014 Mar; 32(7):634-40. PubMed ID: 24449241
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trials.
Ye X; Huang J; Pan Q; Li W
PLoS One; 2013; 8(8):e72635. PubMed ID: 23977334
[TBL] [Abstract][Full Text] [Related]
16. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
Attal M; Lauwers-Cances V; Marit G; Caillot D; Moreau P; Facon T; Stoppa AM; Hulin C; Benboubker L; Garderet L; Decaux O; Leyvraz S; Vekemans MC; Voillat L; Michallet M; Pegourie B; Dumontet C; Roussel M; Leleu X; Mathiot C; Payen C; Avet-Loiseau H; Harousseau JL;
N Engl J Med; 2012 May; 366(19):1782-91. PubMed ID: 22571202
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide maintenance therapy for patients with multiple myeloma: meta-analysis.
Kagoya Y; Nannya Y; Kurokawa M
Leuk Res; 2012 Aug; 36(8):1016-21. PubMed ID: 22579366
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.
Huang H; Zhou L; Peng L; Fu W; Zhang C; Hou J
Leuk Res; 2014 Sep; 38(9):1048-54. PubMed ID: 25052306
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide treatment for patients with previously untreated multiple myeloma: a meta-analysis of randomized controlled trials.
Gao M; Kong Y; Wang H; Xie B; Yang G; Gao L; Zhang Y; Zhan F; Dai B; Tao Y; Shi J
Tumour Biol; 2016 Aug; 37(8):11081-98. PubMed ID: 26906553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
